Background: It is commonly acknowledged that persistent inflammation actively contributes to cancer. The role of inflammatory immunocytes and associated cytokines in the development and spread of colorectal cancer (CRC) is thought to be "double-edged." A pleiotropic proinflammatory cytokine called interleukin-17 (IL-17) can encourage inflammation brought on by cancer and shield cancer cells from immune surveillance. IL-17 is typically regarded as a promoter of CRC advancement despite disagreement. The objective of this study: To investigate the role of IL17 A as an associated factor with CRC by estimating it in tissue biopsy of colorectal cancer (CRC) patients and control using immunohistochemistry assay Patients and methods: This study was conducted from January 2022 to June 2022. Tissue biopsies were collected from a total of 35 colorectal patients, 35 of tumor-adjacent tissue and 35 biopsies of polyp tissue, from patients who had attended the Gastroenterology and Liver Diseases Hospital and 30 normal control tissue were collected from autopsies at the Forensics Medicine Department. H&E stained sections were prepared for histopathological investigation, and positively charged slides were prepared for IL-17A detection using an immunohistochemistry assay. Results: It’s been found that the expression of IL-17A was in the highest frequency in resection tissue (score 1), 17 cases (48.6%) and (score 2) 13 cases of malignant tissue (37.1%), followed by 12 cases (34.3%) of benign tumor tissue in (score 1) with a significant p-value (p=<0.001) in a different type of tissue. According to the staging system it was mostly expressed in patients with extensive tumor invasion (T4) and that appeared in 7 patients (43.80%) compared to patients with T1+T2+T3, with a non-significant P value (P =0.533). Conclusions: It has been found that the expression of IL17A is highly significant in CRC patients and it might have a double-edged role as its important in controlling the intestinal microbiota and getting rid of extracellular bacteria, and its pro-inflammatory effect in tumor development. IL17A expression has no significant value according to the different stages of CRC based on the TNM staging system.
(FULL ARTICLE LINK) Read more ...
2023
|
|
|
